10:00 AM EDT, 10/09/2024 (MT Newswires) -- Capricor Therapeutics ( CAPR ) said Wednesday that it has initiated a rolling submission with the US Food and Drug Administration for a biologics license application for deramiocel to treat patients with Duchenne muscular dystrophy cardiomyopathy.

The biotech company said it expects to complete the rolling submission by the end of the year and that the application may be eligible for priority review.

Price: 18.27, Change: -1.06, Percent Change: -5.48